The article discusses the pursuit to get MDMA approved for PTSD treatment, a young girl’s improvement with genetic medicine, and Merck’s acquisition of a bispecific antibody. A new AI drug development merger is also highlighted, along with Novo’s decision on heart failure treatment. The FDA’s looming decision on MDMA, the potential impact on psychedelics, and drug pricing negotiations are covered. Additional topics include 23andMe’s shift to weight loss, Novavax’s manufacturing plant sale, and FDA approvals. The article also delves into Recursion merging with Exscientia and the latest in biotech VC.
Source link
Novo Nordisk, Recursion, Merck updates
